DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models

202418 citationsJournal Articlegold Open Access

Authors

Shengchao Lin · Duality (United States)

Yu Zhang

Haiqing Hua · Duality (United States)

Abstract

These results suggest that DB-1314 may be a candidate ADC targeting DLL3 for the treatment of DLL3-positive SCLC, supporting further evaluation in the clinical setting.

Topics & Keywords

Lung Cancer Research Studies Cancer therapeutics and mechanisms Neuroendocrine Tumor Research Advances

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Translational Medicine

Volume 22, Issue 1, pp. 766-766

DOI: 10.1186/s12967-024-05568-y

Field-Weighted Citation Impact: 5.11